EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Continued burden of nontuberculous mycobacteria in the screened subpopulations of people with cystic fibrosis receiving CFTR modulator therapy

Silvia M Caceres, Christine Barboa, Sara Vahling, Matthew Strand, Jerry A Nick, Jane E Gross

Journal of Cystic Fibrosis · 2026-11

DOI: 10.1016/j.jcf.2026.10.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-11. Verfasst von Silvia M Caceres und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National Jewish Health, Denver, CO, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nontuberculous mycobacteria (NTM) are respiratory pathogens associated with poor clinical outcomes in people with cystic fibrosis (pwCF). CFTR modulator therapy (CFTRm), particularly elexacaftor/tezacaftor/ivacaftor (ETI), has dramatically improved outcomes in pwCF and is associated with reductions in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. However, impact on NTM remains unclear. We conducted parallel retrospective analyses of NTM trends among pwCF from 2017-2024 using CF Foundation Patient Registry (CFFPR) Annual Reports and surveillance data from National Jewish Health (NJH) Adult CF Program. Annual surveillance rates and NTM culture positivity were evaluated. For NJH longitudinal data (2020-2025), a generalized linear mixed model was used to assess NTM positivity trends, including a random intercept for subjects to account for repeated measures and intermittent missing cultures. From 2017-2024, U.S. and NJH NTM epidemiology showed parallel trends: higher NTM positivity among pwCF with cultures before CFTRm expansion and a decline in years 2020-2021, with increased rates by 2024. NJH consistently reported higher NTM positivity among cultured pwCF, yet patient-level NTM positivity aligned closely with U.S. rates. During the study, respiratory cultures substantially decreased, from 50.3% to 30.2% nationally and from 83.5% to 46.4% at NJH. NTM positivity is stable to increasing. In adjusted models, odds of NTM positivity increased annually by 4.2% nationally and 11.4% at NJH from 2020 to 2024. These findings suggest that CFTRm use decreased NTM culture surveillance, but NTM positivity is increasing. The concordance between national and referral-center data highlights the importance of reprioritizing NTM surveillance among pwCF taking CFTRm.

Schlagwörter

Stichwörter der Autor:innen

CFTR modulatorCystic fibrosisMycobacterium abscessusMycobacterium aviumNontuberculous mycobacteria

Autor:innen und Institutionen

  • Department of Medicine, National Jewish Health, Denver, CO, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.
  • Department of Medicine, National Jewish Health, Denver, CO, USA.
  • Department of Biostatistics, National Jewish Health, Denver, CO, USA.
  • Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA. Electronic address: Jane_Gross@med.unc.edu.

Förderung

  • Cystic Fibrosis Foundation

Zitieren

APA

Caceres, S. M., Barboa, C., Vahling, S., Strand, M., Nick, J. A., & Gross, J. E. (2026). Continued burden of nontuberculous mycobacteria in the screened subpopulations of people with cystic fibrosis receiving CFTR modulator therapy. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.10.004

Vancouver

Caceres SM, Barboa C, Vahling S, Strand M, Nick JA, Gross JE. Continued burden of nontuberculous mycobacteria in the screened subpopulations of people with cystic fibrosis receiving CFTR modulator therapy. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.10.004

BibTeX
@article{Caceres2026,
  author = {Caceres, Silvia M and Barboa, Christine and Vahling, Sara and Strand, Matthew and Nick, Jerry A and Gross, Jane E},
  title = {Continued burden of nontuberculous mycobacteria in the screened subpopulations of people with cystic fibrosis receiving CFTR modulator therapy},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2026.10.004}
}
Kostenlos starten →